Hepatocellular carcinoma (HCC) is one of the most common and lethal malignant tumors in the world. Therapeutic options for advanced HCC are limited. Systemic treatment, especially with conventional cytotoxic drugs, is usually ineffective. For more than a decade, sorafenib has been the only systemic ...
Surgical resection and liver transplant remain the only curative therapies for most patients with hepatocellular carcinoma (HCC). Systemic therapy options have typically been ineffective, but recent advances, such as the combination of immune checkpoint inhibitors and targeted therapies, hav...
Development process for the guideline In 2023, the steering committee of the Asian Pacific Association for the Study of the Liver (APASL) initiated the working party on the use of systemic therapy for HCC. To this end, a panel of experts from different disciplines in the Asia–Pacific region...
Hepatocellular carcinoma (HCC) is one of the most common and lethal malignant tumors in the world. Therapeutic options for advanced HCC are limited. Systemic treatment, especially with conventional cytotoxic drugs, is usually ineffective. For more than a decade, sorafenib has been the only systemic ...
the currently used criteria to determine treatment response or progression might prevent physicians from making appropriate clinical judgements and interpreting evidence arising from trials. In this Review, we discuss the advances in systemic therapy for HCC and critically review trial designs in HCC. Alt...
systemic therapy HCC advanced hepatocellular carcinoma long-term survival Sorry, something went wrong. Please try again and make sure cookies are enabled Cited by (0) Neoadjuvant immunotherapy for early-stage hepatocellular carcinoma: the arts and science ...
t in favor of the control doxorubicin arm.16 The variable results from trials summarized in Table 1 have contributed to the lack of consensus regarding ‘‘standard’’ che-motherapy for patients with advanced HCC; they have also resulted in ongoing debate regarding the best control arm for ...
Areas covered: This review summarizes the standard of care in first-line systemic therapy for patients with advanced HCC and provides an outlook on the most promising combinations currently tested in prospective trials. Expert Opinion: The recent approval of novel substances has substantially changed ...
General considerations concerning systemic therapy for HCC In general, overall survival (OS) of patients treated with systemic agents has gradually improved over time (Table 1). In the first-line setting, the median OS of sorafenib-treated patients has improved from 10.7 months in the SHARP study...
The evolution of systemic therapies has given great improvement of the prognosis for patients with unresectable HCC who are unsuitable for locoregional therapy, including patients with intermediate-stage HCC who will not benefit from transarterial chemoembolization (TACE), such as infiltrative, diffuse, ...